1. Karlov V.A. Epilepsy in children and adults, men and women [Epilepsiya u detei i vzroslykh zhenshchin i muzhchin]. Moscow. 2010; 720 s.
2. Mukhin K.Yu. Idiopathic generalized epilepsy [Idiopaticheskie generalizovannye epilepsii]. Moscow 2000.
3. Mukhin K.Yu. Epileptic encephalopathy [Epilepticheskie entsefalopatii]. Moscow. 2011.
4. Bardai A., Blum M. van Noord C. et al. Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications. Heart. 2014; 1-6.
5. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48: 1308-1317.
6. Berg A.T., Shinnar S., Levy S.R. et al. Early development of intractable epilepsy in children. A prospective study. Neurology. 2001; 56: 1445-1452.
7. Beydoun A., Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology. 2003. 60: 13-25
8. Brodie M.J., Leach J.P. Success or failure with antiepileptic drug therapy: beyond empiricism? Neurology. 2003; 60: 162-163.
9. Brodie M.J., Yuen A.W.C. and the 105 Study Group. Lamotrigine substitution study: synergism with sodium valproate? Epilepsy Res. 1997; 26: 423-432.
10. Brodie M.J. Medical therapy of epilepsy: When to initiate treatment and when to combine? J. Neurol. 2005; 252: 125-130.
11. Deckers C.L.P., Czuczwar S.J., Hekster Y.A. et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000; 41: 1364-1374.
12. Deckers C.L., Hekster Y.A., Keyser A. et all. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia. 1997; 38: 570-5.
13. Engel J., Coulter D.A. Hov to overcome drug resistence in epilepsy? Epilepsy Res. 2006. 69: 245-248
14. Ferrendelli J.A. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology. 1995; 45: 12-16.
15. French J.A. Definition of refractory seizures. Epilepsia. 2007; 48: 3-7.
16. French J.A., Faught E. Rational polytherapy. Epilepsia. 2009; 50 (8): 63-68.
17. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007; 75: 192-196.
18. Johannessen S.I., Landmark C.J. Antiepileptic Drug Interactions - Principles and Clinical Implications. Current Neuropharmacology. 2010; 8: 254-267.
19. Kwan P., Arzimonoglou A., Berg A.T. et al. Definition of drug resistant epilepsy. Consensus proposal by the ad hoc Tasc force of the ILAE Comissijn on Therapeutic Strategies. Epilepsia. 2010; 51 (6): 1069-1077.
20. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med. 2000; 341: 314-319.
21. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000; 9: 464-468.
22. MacDonald B.K., Johnson A.L., Goodridge D.M. et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol. 2000; 48: 8.
23. Mohanraj R., Brodie M.J. Measuring the efficacy of antiepileptic drugs. Seizure. 2003; 12: 413-443.
24. Neligan A et al. Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. J Neurol Neurosurg Psychiatry. 2012 Aug; 83 (8): 810-3.
25. Noack-Rink M et al. Lacosamide as Add-On to Monotherapy in Patients with Partial-Onset Seizures: Interim Results of the Post-Marketing VITOBA Study (VImpaT Added to One Baseline AED). American Academy of Neurology (AAN). Annual Meeting. 2012; P06.126.
26. Panayiotopoulos C.P. Rational polytherapy focal epilepsy. International neurological journal. 2007; 5 (15).
27. Panayotopoulos C.P. Principles of Therapy in Epilepsies. 2010.
28. Patsalos, P.N.; Perucca, E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003; 2: 347-356.
29. Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs. 1998; 10: 171-179.
30. Perucca E. Clinically relevant drug interactions with antiepileptic drugs.Br. J. Clin. Pharmacol. 2006; 61: 246-255.
31. Sake J.K., Hebert D., Isojärvi J. et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010; 24: 1055-68.
32. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70 (1): 54-65.
33. Stephen L.J., Kwan P., Brodie M.J. Does the cause of localization-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia. 2001; 42: 357-362.
34. Stephen L.J., Kelly K., Parker P., Brodie M.J. Adjunctive lacosamide in clinical practice: sodium blockadewith a difference? Epilepsy Behav. 2011; 22 (3): 499-504.
35. Trevathan E., Gilliam F. Lost years. Delayed referral for surgically treatable epilepsy. Neurology. 2003; 61: 432-433.
36. Villanueva V., López F.J., Serratosa J.M. et all. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy & Behavior. 2013; 29: 349-356.
37. Villanueva V., Serratosa JM., Guillamon E. et all. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-years ESLIBASE retrospective study. Epilepsy research. 2014; 108 (7). https://doi.org/http://dx.doi.org./10.1016/j.eplepsyres.2014.05.005/.
Email this article 
